U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Acute Myelomonocytic Leukemia

MedGen UID:
1758507
•Concept ID:
C5420825
•
Neoplastic Process

Definition

Acute myelomonocytic leukemia that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Acute Myelomonocytic Leukemia

Professional guidelines

PubMed

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol 2013 Feb;88(2):141-50. doi: 10.1002/ajh.23384. PMID: 23349007
Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol 2011 Dec;86(12):1017-26. doi: 10.1002/ajh.22210. PMID: 22086865
Radioimmunoconjugates in acute leukemia treatment: the future is radiant.
Kotzerke J, Bunjes D, Scheinberg DA
Bone Marrow Transplant 2005 Dec;36(12):1021-6. doi: 10.1038/sj.bmt.1705182. PMID: 16247432

Recent clinical studies

Etiology

Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
Cunningham L, Merguerian M, Calvo KR, Davis J, Deuitch NT, Dulau-Florea A, Patel N, Yu K, Sacco K, Bhattacharya S, Passi M, Ozkaya N, De Leon S, Chong S, Craft K, Diemer J, Bresciani E, O'Brien K, Andrews EJ, Park N, Hathaway L, Cowen EW, Heller T, Ryan K, Barochia A, Nghiem K, Niemela J, Rosenzweig S, Young DJ, Frischmeyer-Guerrerio PA, Braylan R, Liu PP
Blood 2023 Dec 21;142(25):2146-2158. doi: 10.1182/blood.2023019746. PMID: 37738626Free PMC Article
Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases.
Song X, Qi J, Li X, Zhou M, He J, Chu T, Han Y
Platelets 2023 Dec;34(1):2229905. doi: 10.1080/09537104.2023.2229905. PMID: 37409458
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G
Lancet Haematol 2022 Oct;9(10):e756-e765. Epub 2022 Sep 2 doi: 10.1016/S2352-3026(22)00216-2. PMID: 36063832
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY
Lancet Haematol 2020 Oct;7(10):e724-e736. Epub 2020 Sep 5 doi: 10.1016/S2352-3026(20)30210-6. PMID: 32896301Free PMC Article
Decitabine/Cedazuridine: First Approval.
Dhillon S
Drugs 2020 Sep;80(13):1373-1378. doi: 10.1007/s40265-020-01389-7. PMID: 32860582Free PMC Article

Diagnosis

Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
Cunningham L, Merguerian M, Calvo KR, Davis J, Deuitch NT, Dulau-Florea A, Patel N, Yu K, Sacco K, Bhattacharya S, Passi M, Ozkaya N, De Leon S, Chong S, Craft K, Diemer J, Bresciani E, O'Brien K, Andrews EJ, Park N, Hathaway L, Cowen EW, Heller T, Ryan K, Barochia A, Nghiem K, Niemela J, Rosenzweig S, Young DJ, Frischmeyer-Guerrerio PA, Braylan R, Liu PP
Blood 2023 Dec 21;142(25):2146-2158. doi: 10.1182/blood.2023019746. PMID: 37738626Free PMC Article
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY
Lancet Haematol 2020 Oct;7(10):e724-e736. Epub 2020 Sep 5 doi: 10.1016/S2352-3026(20)30210-6. PMID: 32896301Free PMC Article
Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
Lyle L, Daver N
Am J Manag Care 2018 Aug;24(16 Suppl):S356-S365. PMID: 30132679
Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol 2011 Dec;86(12):1017-26. doi: 10.1002/ajh.22210. PMID: 22086865
Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined.
Elliott MA
Best Pract Res Clin Haematol 2006;19(3):571-93. doi: 10.1016/j.beha.2005.07.012. PMID: 16781489

Therapy

Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
Cunningham L, Merguerian M, Calvo KR, Davis J, Deuitch NT, Dulau-Florea A, Patel N, Yu K, Sacco K, Bhattacharya S, Passi M, Ozkaya N, De Leon S, Chong S, Craft K, Diemer J, Bresciani E, O'Brien K, Andrews EJ, Park N, Hathaway L, Cowen EW, Heller T, Ryan K, Barochia A, Nghiem K, Niemela J, Rosenzweig S, Young DJ, Frischmeyer-Guerrerio PA, Braylan R, Liu PP
Blood 2023 Dec 21;142(25):2146-2158. doi: 10.1182/blood.2023019746. PMID: 37738626Free PMC Article
Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases.
Song X, Qi J, Li X, Zhou M, He J, Chu T, Han Y
Platelets 2023 Dec;34(1):2229905. doi: 10.1080/09537104.2023.2229905. PMID: 37409458
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G
Lancet Haematol 2022 Oct;9(10):e756-e765. Epub 2022 Sep 2 doi: 10.1016/S2352-3026(22)00216-2. PMID: 36063832
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY
Lancet Haematol 2020 Oct;7(10):e724-e736. Epub 2020 Sep 5 doi: 10.1016/S2352-3026(20)30210-6. PMID: 32896301Free PMC Article
Decitabine/Cedazuridine: First Approval.
Dhillon S
Drugs 2020 Sep;80(13):1373-1378. doi: 10.1007/s40265-020-01389-7. PMID: 32860582Free PMC Article

Prognosis

Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
Cunningham L, Merguerian M, Calvo KR, Davis J, Deuitch NT, Dulau-Florea A, Patel N, Yu K, Sacco K, Bhattacharya S, Passi M, Ozkaya N, De Leon S, Chong S, Craft K, Diemer J, Bresciani E, O'Brien K, Andrews EJ, Park N, Hathaway L, Cowen EW, Heller T, Ryan K, Barochia A, Nghiem K, Niemela J, Rosenzweig S, Young DJ, Frischmeyer-Guerrerio PA, Braylan R, Liu PP
Blood 2023 Dec 21;142(25):2146-2158. doi: 10.1182/blood.2023019746. PMID: 37738626Free PMC Article
Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases.
Song X, Qi J, Li X, Zhou M, He J, Chu T, Han Y
Platelets 2023 Dec;34(1):2229905. doi: 10.1080/09537104.2023.2229905. PMID: 37409458
Decitabine/Cedazuridine: First Approval.
Dhillon S
Drugs 2020 Sep;80(13):1373-1378. doi: 10.1007/s40265-020-01389-7. PMID: 32860582Free PMC Article
Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
Lyle L, Daver N
Am J Manag Care 2018 Aug;24(16 Suppl):S356-S365. PMID: 30132679
Hypoplastic myelodysplastic syndrome.
Nand S, Godwin JE
Cancer 1988 Sep 1;62(5):958-64. doi: 10.1002/1097-0142(19880901)62:5<958::aid-cncr2820620519>3.0.co;2-p. PMID: 3409176

Clinical prediction guides

Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.
Zhao L, Yang J, Chen M, Xiang X, Ma H, Niu T, Gong Y, Chen X, Liu J, Wu Y
Ann Hematol 2024 Apr;103(4):1197-1209. Epub 2024 Feb 8 doi: 10.1007/s00277-024-05646-7. PMID: 38329487
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.
Murphy T, Mason JM, Leber B, Bray MR, Chan SM, Gupta V, Khalaf D, Maze D, McNamara CJ, Schimmer AD, Schuh AC, Sibai H, Trus M, Valiquette D, Martin K, Nguyen L, Li X, Mak TW, Minden MD, Yee KWL
Leukemia 2024 Mar;38(3):502-512. Epub 2023 Dec 19 doi: 10.1038/s41375-023-02110-9. PMID: 38114624
Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
Cunningham L, Merguerian M, Calvo KR, Davis J, Deuitch NT, Dulau-Florea A, Patel N, Yu K, Sacco K, Bhattacharya S, Passi M, Ozkaya N, De Leon S, Chong S, Craft K, Diemer J, Bresciani E, O'Brien K, Andrews EJ, Park N, Hathaway L, Cowen EW, Heller T, Ryan K, Barochia A, Nghiem K, Niemela J, Rosenzweig S, Young DJ, Frischmeyer-Guerrerio PA, Braylan R, Liu PP
Blood 2023 Dec 21;142(25):2146-2158. doi: 10.1182/blood.2023019746. PMID: 37738626Free PMC Article
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
Gadaud N, Leroy H, Bérard E, Tavitian S, Leguay T, Dimicoli-Salazar S, Rieu JB, Luquet I, Largeaud L, Bidet A, Delabesse E, Klein E, Sarry A, de Grande AC, Bories P, Pigneux A, Récher C, Dumas PY, Bertoli S
Leuk Lymphoma 2022 Jun;63(6):1398-1406. Epub 2022 Jan 4 doi: 10.1080/10428194.2021.2022140. PMID: 35634787
Decitabine/Cedazuridine: First Approval.
Dhillon S
Drugs 2020 Sep;80(13):1373-1378. doi: 10.1007/s40265-020-01389-7. PMID: 32860582Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...